MDSpire - Summary
From the Journals

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

Share

A prospective cohort study published in The Lancet Neurology reveals that the combination of two plasma biomarkers, eMTBR-tau243 and p-tau217, can effectively identify established Alzheimer’s disease and predict cognitive decline in patients with amyloid pathology. This study evaluated 572 patients and found that the combined use of these biomarkers improved diagnostic accuracy and predictive value. Elevated eMTBR-tau243 correlates with tau pathology and cognitive deterioration, suggesting a two-step testing method could distinguish asymptomatic from symptomatic Alzheimer’s patients, with potential implications for therapy selection.

Original Source(s)

A Two-Biomarker Signal for Alzheimer’s Disease

  • by Henry Thomas

  • March 30, 2026

Related Content

Surgical Approaches Evolve in Tremor Syndromes

Evidence review highlights expanding role of neuromodulation and lesioning, with differences across tremor types

Progesterone Linked to Brain Structure Changes

MRI study finds stronger associations than estradiol across menstrual phases

Reducing Constipation in Parkinson’s, Step by Step

A 3-month walking program was associated with improved constipation symptoms and lower Parkinson’s disease severity scores in a small uncontrolled pre–post study